Karyopharm Therapeutics Inc. (KPTI)
NASDAQ: KPTI · Real-Time Price · USD
7.14
-0.53 (-6.91%)
At close: May 18, 2026, 4:00 PM EDT
7.02
-0.12 (-1.68%)
After-hours: May 18, 2026, 4:27 PM EDT
Karyopharm Therapeutics Revenue
Karyopharm Therapeutics had revenue of $35.07M in the quarter ending March 31, 2026, with 16.83% growth. This brings the company's revenue in the last twelve months to $151.12M, up 6.33% year-over-year. In the year 2025, Karyopharm Therapeutics had annual revenue of $146.07M with 0.57% growth.
Revenue (ttm)
$151.12M
Revenue Growth
+6.33%
P/S Ratio
1.06
Revenue / Employee
$662,798
Employees
228
Market Cap
161.02M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 146.07M | 830.00K | 0.57% |
| Dec 31, 2024 | 145.24M | -796.00K | -0.55% |
| Dec 31, 2023 | 146.03M | -11.04M | -7.03% |
| Dec 31, 2022 | 157.07M | -52.75M | -25.14% |
| Dec 31, 2021 | 209.82M | 101.73M | 94.12% |
| Dec 31, 2020 | 108.09M | 67.19M | 164.31% |
| Dec 31, 2019 | 40.89M | 10.56M | 34.80% |
| Dec 31, 2018 | 30.34M | 28.73M | 1,790.09% |
| Dec 31, 2017 | 1.61M | 1.45M | 942.21% |
| Dec 31, 2016 | 154.00K | -96.00K | -38.40% |
| Dec 31, 2015 | 250.00K | 21.00K | 9.17% |
| Dec 31, 2014 | 229.00K | -158.00K | -40.83% |
| Dec 31, 2013 | 387.00K | -247.00K | -38.96% |
| Dec 31, 2012 | 634.00K | 482.00K | 317.11% |
| Dec 31, 2011 | 152.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Heron Therapeutics | 150.71M |
| Protalix BioTherapeutics | 76.38M |
| Spero Therapeutics | 61.19M |
| Precision BioSciences | 45.07M |
| ProQR Therapeutics | 15.73M |
KPTI News
- 4 days ago - Karyopharm reports Q1 EPS ($1.24), consensus ($1.44) - TheFly
- 4 days ago - Karyopharm sees 2026 revenue $130M-$150M, consensus $137.49M - TheFly
- 4 days ago - Karyopharm Therapeutics Earnings Call Transcript: Q1 2026 - Transcripts
- 4 days ago - Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment - PRNewsWire
- 6 days ago - Karyopharm to Participate at Upcoming Investor Conferences - PRNewsWire
- 11 days ago - Karyopharm to Report First Quarter 2026 Financial Results on May 14, 2026 - PRNewsWire
- 11 days ago - Karyopharm price target raised to $13 from $8 at H.C. Wainwright - TheFly
- 14 days ago - Karyopharm files $400M mixed securities shelf - TheFly